In a recent patent dispute, Lupin, an international pharmaceutical company, has achieved a legal victory against Galderma. Galderma had accused Lupin of infringing upon two of its patents, which cover a rosacea drug. However, the judge overseeing the case found that Galderma’s allegations lacked sufficient proof.
The judge emphatically stated that “Galderma has a theory but no proof,” thereby effectively dismissing Galderma’s claims against Lupin. This decision marks a noteworthy win for Lupin in the competitive landscape of pharmaceutical patents, particularly in the realm of rosacea treatments.
The full details of the case and its implications for the pharmaceutical industry are available at Law360, a platform offering comprehensive legal news and analysis.